Anhui Sunhere Pharmaceutical Excipients Co.,Ltd.

SZSE:300452 Stock Report

Market Cap: CN¥2.9b

Anhui Sunhere Pharmaceutical ExcipientsLtd Past Earnings Performance

Past criteria checks 3/6

Anhui Sunhere Pharmaceutical ExcipientsLtd has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13.6% per year. Anhui Sunhere Pharmaceutical ExcipientsLtd's return on equity is 16.6%, and it has net margins of 19%.

Key information

16.1%

Earnings growth rate

16.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate13.6%
Return on equity16.6%
Net Margin19.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Anhui Sunhere Pharmaceutical ExcipientsLtd's (SZSE:300452) Earnings Are Weaker Than They Seem

Sep 03
Anhui Sunhere Pharmaceutical ExcipientsLtd's (SZSE:300452) Earnings Are Weaker Than They Seem

Recent updates

Anhui Sunhere Pharmaceutical ExcipientsLtd's (SZSE:300452) Earnings Are Weaker Than They Seem

Sep 03
Anhui Sunhere Pharmaceutical ExcipientsLtd's (SZSE:300452) Earnings Are Weaker Than They Seem

Anhui Sunhere Pharmaceutical ExcipientsLtd (SZSE:300452) Has Affirmed Its Dividend Of CN¥0.25

May 26
Anhui Sunhere Pharmaceutical ExcipientsLtd (SZSE:300452) Has Affirmed Its Dividend Of CN¥0.25

Revenue & Expenses Breakdown

How Anhui Sunhere Pharmaceutical ExcipientsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300452 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248431606540
30 Jun 248361696242
31 Mar 248291626141
31 Dec 238391626042
30 Sep 238201605541
30 Jun 237971535440
31 Mar 237611465238
01 Jan 237051315134
30 Sep 226961115234
30 Jun 226711025233
31 Mar 22636925230
31 Dec 21617895227
30 Sep 21599985021
30 Jun 21579974721
31 Mar 215791014320
31 Dec 20531944318
30 Sep 20514914817
30 Jun 20499935317
31 Mar 20474896017
31 Dec 19464846116
30 Sep 19446825917
30 Jun 19437785716
31 Mar 19435745715
31 Dec 18429705514
30 Sep 18422665113
30 Jun 18400594615
31 Mar 18373554411
31 Dec 1733950439
30 Sep 1731147416
30 Jun 1729747460
31 Mar 1729248450
31 Dec 1628649450
30 Sep 1627449440
30 Jun 1626951440
31 Mar 1626147430
31 Dec 1525944430
30 Sep 1525443400
30 Jun 1524936400
31 Mar 1524635390
31 Dec 1423935380
31 Dec 1321335330

Quality Earnings: 300452 has high quality earnings.

Growing Profit Margin: 300452's current net profit margins (19%) are lower than last year (19.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300452's earnings have grown by 16.1% per year over the past 5 years.

Accelerating Growth: 300452's earnings growth over the past year (0.5%) is below its 5-year average (16.1% per year).

Earnings vs Industry: 300452 earnings growth over the past year (0.5%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 300452's Return on Equity (16.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:53
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Tan Huan GanCitic Securities Co., Ltd.
Shitong HanCitic Securities Co., Ltd.